

Please type a plus (+) inside this box

12-20-99

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

9196-0018-999

Total Pages

First Named Inventor or Application Identifier

Dasseux et al.

Express Mail Label No.

EL 451 593 357 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification [Total Pages 144]
(preferred arrangement set forth below)
-Descriptive title of the Invention
-Cross Reference to Related Applications
-Statement Regarding Fed sponsored R&D
-Reference to Microfiche Appendix
-Background of the Invention
-Brief Summary of the Invention
-Brief Description of the Drawings (if filed)
-Detailed Description of the Invention (including drawings, if filed)
-Claim(s)
-Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 14]
4. ☒ Oath or Declaration [Total Sheets 2]
a. ☐ Newly executed (original or copy)
b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
i. ☐ **DELETION OF INVENTORS(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. ☐ Computer Readable Copy
b. ☒ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/940,096 filed September 29, 1997.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

APOLIPOPROTEIN A-I AGONISTS AND THEIR USE
TO TREAT DYSLIPIDEMIC DISORDERS

BY:

Jean-Louis Dasseux (France)
Isoldestr. 27
D-68199 Mannheim
Germany

Renate Sekul (Germany)
Wichernstr. 13
D-68526 Ladenburg
Germany

Klaus Büttner (Germany)
Eichendorffstr. 6
D-74925 Epfenbach
Germany

Isabelle Cornut (France)
Meisenweg 10
D-68535 Edingen-Neckarhausen
Germany

Günther Metz (Germany)
Lessingstr. 14
D-68535 Edingen-Neckarhausen
Germany

Laura A. Coruzzi

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

APOLIPOPROTEIN A-I AGONISTS AND THEIR USE
TO TREAT DYSLIPIDEMIC DISORDERS

TABLE OF CONTENTS

		<u>Page</u>
5	1. INTRODUCTION	-1-
10	2. BACKGROUND OF THE INVENTION	-1-
	2.1. CHOLESTEROL TRANSPORT	-2-
	2.2. REVERSE CHOLESTEROL TRANSPORT	-4-
	2.3. CURRENT TREATMENTS FOR DYSLIPOPROTEINEMIAS	-7-
15	2.4. ApoA-I AS A TARGET	-10-
	3. SUMMARY OF THE INVENTION	-17-
	3.1. ABBREVIATIONS	-18-
	3.2. DEFINITIONS	-19-
20	4. BRIEF DESCRIPTION OF THE FIGURES	-21-
	5. DETAILED DESCRIPTION OF THE INVENTION	-24-
	5.1. PEPTIDE STRUCTURE AND FUNCTION	-25-
	5.1.1. ANALYSIS OF STRUCTURE AND FUNCTION	-62-
25	5.1.2. PREFERRED EMBODIMENTS	-65-
	5.2. SYNTHESIS AND PURIFICATION OF THE ApoA-I PEPTIDE AGONISTS	-70-
	5.2.1. CHEMICAL SYNTHESIS	-70-
	5.2.2. RECOMBINANT SYNTHESIS	-72-
30	5.2.3. PURIFICATION OF PEPTIDES	-76-
	5.3. PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT	-78-
	5.3.1. ApoA-I AGONISTS AND PEPTIDE/LIPID COMPLEX AS THE ACTIVE INGREDIENT	-79-
35	5.3.2. METHODS OF THE TREATMENT	-83-
	5.3.3. PHARMACEUTICAL FORMULATIONS	-85-
	5.4. OTHER USES	-87-
40	6. EXAMPLE: SYNTHESIS OF PEPTIDE AGONISTS OF ApoA-I	-88-
	6.1. SYNTHESIS OF CORE PEPTIDES	-88-

		<u>Page</u>
	6.2 SYNTHESIS OF PEPTIDE AMIDES	-90-
	6.3 SYNTHESIS OF N-TERMINAL ACYLATED PEPTIDES . .	-90-
	6.4 CLEAVAGE AND DEPROTECTION	-90-
	6.5 PURIFICATION	-91-
5	6.6 CHARACTERIZATION	-91-
	6.6.1 LC-MS	-92-
	6.6.2 AMINO ACID ANALYSIS	-92-
	6.7 SYNTHESIS OF BRANCHED NETWORKS	-93-
10	7. EXAMPLE: STRUCTURAL AND LIPID BINDING ANALYSIS OF ApoA-I PEPTIDES	-93-
	7.1 CIRCULAR DICHROISM	-94-
	7.1.1 EXPERIMENTAL METHOD	-94-
	7.1.2 HELICITY DETERMINATION	-95-
15	7.2 FLUORESCENCE SPECTROSCOPY	-96-
	7.2.1 FLUORESCENCE SPECTRAL ANALYSIS	-97-
	7.2.2 RESULTS AND DISCUSSION	-98-
	7.3 NUCLEAR MAGNETIC RESONANCE (NMR)	-99-
	7.3.1 NMR SAMPLE PREPARATION	-99-
20	7.3.2 NMR SPECTROSCOPY	-99-
	7.3.3 NMR ASSIGNMENT	-100-
	7.3.4 RESULTS AND DISCUSSION	-100-
25	8. EXAMPLE: LCAT ACTIVATION ASSAY	-102-
	8.1 PREPARATION OF SUBSTRATE VESICLES	-103-
	8.2 PURIFICATION OF LCAT	-103-
	8.2.1 PREPARATION OF LPDS	-105-
	8.2.2 PHENYLSEPHAROSE CHROMATOGRAPHY	-105-
	8.2.3 AFFIGELBLUE CHROMATOGRAPHY	-105-
30	8.2.4 ConA CHROMATOGRAPHY	-106-
	8.2.5 ANTI-ApoA-I AFFINITY CHROMATOGRAPHY .	-106-
	8.3 RESULTS	-106-
35	9. EXAMPLE: PHARMACOKINETICS OF THE ApoA-I AGONISTS .	-122-
	9.1. SYNTHESIS OF RADIOLABELLED PEPTIDES	-122-
	9.2. PHARMACOKINETICS IN MICE	-123-

		<u>Page</u>
	9.3. STABILITY IN HUMAN SERUM	-123-
	9.3.1. EXPERIMENTAL METHODS	-123-
	9.4. FORMATION OF PRE- β LIKE PARTICLES	-123-
	9.4.1. EXPERIMENTAL METHOD	-123-
5	9.5. ASSOCIATION OF Apo-A-I AGONISTS WITH HUMAN LIPOPROTEINS	-124-
	9.5.1. EXPERIMENTAL METHODS	-124-
	9.6. THE ApoA-I AGONISTS OF THE INVENTION SELECTIVELY BIND HDL LIPIDS IN HUMAN PLASMA	-125-
10	9.6.1. EXPERIMENTAL METHOD	-125-
	10. EXAMPLE: THE ApoA-I AGONISTS PROMOTE CHOLESTEROL EFFLUX	-125-
15	11. EXAMPLE: USE OF THE ApoA-I AGONISTS IN ANIMAL MODEL SYSTEMS	-126-
	11.1. PREPARATION OF THE PHOSPHOLIPID/PEPTIDE COMPLEXES	-126-
20	11.2. ISOLATION AND CHARACTERIZATION OF THE PEPTIDE/PHOSPHOLIPID PARTICLES	-127-
	11.3. INJECTION IN THE RABBIT	-127-
	11.4. ANALYSIS OF THE RABBIT SERA	-127-
	11.5. RESULTS	-128-
25	12. EXAMPLE: PREPARATION OF PEPTIDE-LIPID COMPLEX BY CO-LYOPHILIZATION APPROACH	-129-
	12.1. CHARACTERIZATION OF COMPLEXES BY SUPEROSE 6 GEL FILTRATION CHROMATOGRAPHY	-129-
30	13. EXAMPLE: PREPARATION OF ANTIBODIES	-131-